There are 2934 resources available
2348 - Docetaxel for hormone-naïve prostate cancer: results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burden
Presenter: Nicholas James
Session: Proffered Paper – Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
Neurological complications of immunotherapy
Presenter: Matthias Preusser
Session: CNS complications and management in systemic cancer patients
Resources:
Slides
Webcast
The value of PD-L1 as a biomarker beyond lung cancers
Presenter: Kevin Harrington
Session: Current markers in immunotherapy
Resources:
Slides
Webcast
Targeting the microenvironment
Presenter: Florent Petitprez
Session: Current markers in immunotherapy
Resources:
Slides
Webcast
Ex-vivo and 3D models: From mice to men
Presenter: Jos Jonkers
Session: Preclinical models and imaging to guide clinical therapy
Resources:
Slides
Webcast
Imaging of the immune system
Presenter: Tony Lahoutte
Session: Preclinical models and imaging to guide clinical therapy
Resources:
Slides
Webcast
Checkpoint inhibitors in special populations
Presenter: Alexander Menzies
Session: Special clinical scenarios in management of advanced melanoma
Resources:
Slides
Webcast
When can we stop immunotherapy in patients with clinical benefit?
Presenter: Dirk Schadendorf
Session: Special clinical scenarios in management of advanced melanoma
Resources:
Slides
Webcast
Introduction: Where can patient care plans/national guidelines fit into NCCP?
Presenter: Jose Martin-Moreno
Session: The role of the medical oncologist in health policy: Using national cancer control plans to translate science into better patient care
Resources:
Slides
Webcast
The National Cancer Control Plan of Uzbekistan: Update on progress from 2015 to 2019
Presenter: Mirzagaleb Tillyashaykhov
Session: The role of the medical oncologist in health policy: Using national cancer control plans to translate science into better patient care
Resources:
Slides
Webcast